287 related articles for article (PubMed ID: 36927491)
1. Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications.
Gonzalez-Ortiz F; Kac PR; Brum WS; Zetterberg H; Blennow K; Karikari TK
Mol Neurodegener; 2023 Mar; 18(1):18. PubMed ID: 36927491
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Janelidze S; Zetterberg H; Scheffler M; Assal F; Garibotto V; Blennow K; Hansson O; Frisoni GB
J Neurol; 2024 Apr; 271(4):2053-2066. PubMed ID: 38195896
[TBL] [Abstract][Full Text] [Related]
3. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
Kac PR; Gonzalez-Ortiz F; Simrén J; Dewit N; Vanmechelen E; Zetterberg H; Blennow K; Ashton NJ; Karikari TK
Alzheimers Res Ther; 2022 May; 14(1):65. PubMed ID: 35545792
[TBL] [Abstract][Full Text] [Related]
5. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
Ossenkoppele R; van der Kant R; Hansson O
Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated tau in Alzheimer's disease.
Telser J; Grossmann K; Wohlwend N; Risch L; Saely CH; Werner P
Adv Clin Chem; 2023; 116():31-111. PubMed ID: 37852722
[TBL] [Abstract][Full Text] [Related]
7. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Lantero Rodriguez J; Karikari TK; Suárez-Calvet M; Troakes C; King A; Emersic A; Aarsland D; Hye A; Zetterberg H; Blennow K; Ashton NJ
Acta Neuropathol; 2020 Sep; 140(3):267-278. PubMed ID: 32720099
[TBL] [Abstract][Full Text] [Related]
8. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
[TBL] [Abstract][Full Text] [Related]
10. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology.
Kac PR; González-Ortiz F; Emeršič A; Dulewicz M; Koutarapu S; Turton M; An Y; Smirnov D; Kulczyńska-Przybik A; Varma VR; Ashton NJ; Montoliu-Gaya L; Camporesi E; Winkel I; Paradowski B; Moghekar A; Troncoso JC; Lashley T; Brinkmalm G; Resnick SM; Mroczko B; Kvartsberg H; Gregorič Kramberger M; Hanrieder J; Čučnik S; Harrison P; Zetterberg H; Lewczuk P; Thambisetty M; Rot U; Galasko D; Blennow K; Karikari TK
Nat Commun; 2024 Mar; 15(1):2615. PubMed ID: 38521766
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
12. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
[TBL] [Abstract][Full Text] [Related]
13. Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer's Disease.
Babić Leko M; Krbot Skorić M; Klepac N; Borovečki F; Langer Horvat L; Vogrinc Ž; Sonicki Z; Hof PR; Šimić G
Curr Alzheimer Res; 2018; 15(13):1244-1260. PubMed ID: 30207231
[TBL] [Abstract][Full Text] [Related]
14. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.
Spiegel J; Pirraglia E; Osorio RS; Glodzik L; Li Y; Tsui W; Saint Louis LA; Randall C; Butler T; Xu J; Zinkowski RP; Zetterberg H; Fortea J; Fossati S; Wisniewski T; Davies P; Blennow K; de Leon MJ
J Alzheimers Dis; 2016; 49(1):93-100. PubMed ID: 26444757
[TBL] [Abstract][Full Text] [Related]
15. Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study.
Montoliu-Gaya L; Alosco ML; Yhang E; Tripodis Y; Sconzo D; Ally M; Grötschel L; Ashton NJ; Lantero-Rodriguez J; Sauer M; Gomes B; Nilsson J; Brinkmalm G; Sugarman MA; Aparicio HJ; Martin B; Palmisano JN; Steinberg EG; Simkin I; Turk KW; Budson AE; Au R; Farrer L; Jun GR; Kowall NW; Stern RA; Goldstein LE; Qiu WQ; Mez J; Huber BR; Alvarez VE; McKee AC; Zetterberg H; Gobom J; Stein TD; Blennow K
Acta Neuropathol; 2023 Dec; 147(1):5. PubMed ID: 38159140
[TBL] [Abstract][Full Text] [Related]
16. Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease.
Pilotto A; Parigi M; Bonzi G; Battaglio B; Ferrari E; Mensi L; Benussi A; Caratozzolo S; Cosseddu M; Turrone R; Archetti S; Ashton NJ; Zetterberg H; Giliani S; Padovani A
J Alzheimers Dis; 2022; 87(3):991-997. PubMed ID: 35404280
[TBL] [Abstract][Full Text] [Related]
17. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
18. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
[TBL] [Abstract][Full Text] [Related]
19. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.
Zetterberg H; Blennow K
Mol Neurodegener; 2021 Feb; 16(1):10. PubMed ID: 33608044
[TBL] [Abstract][Full Text] [Related]
20. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Janelidze S; Mattsson N; Palmqvist S; Smith R; Beach TG; Serrano GE; Chai X; Proctor NK; Eichenlaub U; Zetterberg H; Blennow K; Reiman EM; Stomrud E; Dage JL; Hansson O
Nat Med; 2020 Mar; 26(3):379-386. PubMed ID: 32123385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
